Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
NCT03286738
·
clinicaltrials.gov ↗
UNKNOWN
Status
1800
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
FOLFIRI, target agent
Sponsor
Joong Bae Ahn